New research published today in Blood Advances finds that young adult Black patients with acute myeloid leukemia (AML), an aggressive and fast-growing form of blood cancer, were five times more likely than comparable white ...
Jul 5, 2022
0
7
Researchers from Rice University and the University of Texas MD Anderson Cancer Center have discovered potential new drugs that work in concert with other drugs to deliver a deadly one-two punch to leukemia.
Jun 30, 2022
0
65
Researchers led by the Francis Crick Institute have found that blocking a particular protein could offer a new way to target leukemic stem cells without causing harm to healthy stem cells.
Jun 23, 2022
0
60
Investigators from Cedars-Sinai Cancer have discovered that cancerous tumors called soft-tissue sarcomas produce a protein that switches immune cells from tumor-attacking to tumor-promoting. The study, published today in ...
Jun 21, 2022
0
285
Leukemia starts in cells that would normally develop into different types of blood cells. About 61,000 people in the U.S. are diagnosed each year, and depending on the type of leukemia and the age of the patient, five-year ...
Jun 8, 2022
0
27
Researchers from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) have found that oral administration of rapamycin to an Alzheimer's disease mouse model causes an increase in beta (β)-amyloid ...
Jun 7, 2022
0
312
The repurposing of FDA-approved drugs for alternative diseases is a faster way of bringing new treatments into the clinic. Researchers at Karolinska Institutet in Sweden have repurposed a cancer drug for treatment of neuroinflammatory ...
Jun 6, 2022
0
109
Imatinib, better known as Gleevec, was hailed as a "miracle" cancer drug when it entered the market in the early 2000s. Though it has been highly successful at treating early-stage chronic myeloid leukemia (CML)—a rare ...
Jun 1, 2022
0
150
Research led by Peter Mac and published in Cancer Discovery has found a new combination therapy for acute myeloid leukemia (AML) that shows greater potency in a preclinical study than either drug used alone.
Jun 1, 2022
0
47
Hypomethylating agents (HMA) are currently used as a first-line treatment for patients with myelodysplastic syndrome (MDS), and increasingly in other diseases, but their mechanism of action is not clear. HMAs may affect many ...
May 26, 2022
0
18
